Burcon NutraScience Corp BRCNF
—
1.00
0.09
9.89%
as of 25 Sep
- Market cap
- —
- P/E
- 0.0×
Follow BRCNF
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
38.18 | 14.43 | 10.76 | 7.52 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(15.41) | (14.10) | (8.11) | (10.13) | |
P/B ratio |
235.61 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
70.04 | 28.67 | 20.98 | 15.40 | |
EV/EBITDA |
526.60 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.99) | (0.75) | (5.18) | (5.55) | |
EV/FCF |
(0.94) | (0.70) | (4.69) | (5.06) | |
Quick Ratio |
0.19 | 0.14 | 0.13 | 0.14 | |
Current Ratio |
0.25 | 0.22 | 0.19 | 0.21 | |
Net Debt/EBITDA |
(2.92) | (8.30) | (7.58) | (8.66) | |
Debt/Assets |
33.58% | 93.56% | 104.77% | 112.51% | |
Debt/Equity |
63.86 | (9.02) | (4.15) | (2.88) | |
Asset Turnover |
0.05 | 0.09 | 0.08 | 0.13 | |
Operating CF/Net income |
0.55 | 0.42 | 0.83 | 0.63 | |
Capex/Depreciation |
(0.76) | (1.02) | (0.55) | (0.25) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
106.29% | 51.34% | (5.48%) | 18.25% | |
Selling, General and Administrative Expense of Revenue |
216.97% | 93.68% | 87.07% | 61.73% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
47.09% | 13.71% | 17.33% | 16.20% | |
Graham Net Nets |
(0.71) | (1.11) | (1.08) | (1.21) | |
Graham Number |
0.00 | 1.56 | 2.47 | 3.12 | |
Earnings Yield |
(44.25%) | (63.64%) | (58.99%) | (61.31%) | |
Free Cash Flow Yield |
(196.05%) | (283.07%) | (41.53%) | (40.49%) | |
Revenue per Share |
0.02 | 0.04 | 0.05 | 0.07 | |
Operating CF per Share |
(0.11) | (0.09) | (0.17) | (0.14) | |
Capex per Share |
(0.03) | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.14) | (0.09) | (0.18) | (0.14) | |
Cash per Share |
0.10 | 0.07 | 0.05 | 0.05 | |
Shareholders Equity per Share |
0.01 | (0.14) | (0.33) | (0.52) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.01 | (0.14) | (0.33) | (0.52) | |
Free Cash Flow |
(1.81) | (1.18) | (2.29) | (1.76) | |
Working Capital |
(5.96) | (6.95) | (7.66) | (8.11) | |
Capital Expenditures |
(0.38) | (0.09) | (0.12) | (0.04) | |
Net Current Asset Value |
(15.71) | (17.04) | (19.08) | (21.12) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
1.46 | 0.16 | 0.20 | 0.04 | |
Net Profit Margin |
(1,005.90%) | (483.72%) | (436.86%) | (295.90%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.26 | 0.19 | 0.30 | 0.61 | |
Average Payables |
0.77 | 1.04 | 1.21 | 1.29 | |
Average Inventory |
0.24 | 0.38 | 0.26 | 0.41 | |
Average Assets |
12.41 | 11.65 | 19.34 | 18.13 | |
Average Common Equity |
0.65 | (0.92) | 0.40 | (1.97) |
Columns are period end dates